TipRanks
Advertisement
Advertisement

ITOS Stock Latest News

Officina Stellare Earns Buy Rating on Strong H1 2026 Results and Sustained Space-Segment Momentum, Backing €56.8 Price Target
RatingsOfficina Stellare Earns Buy Rating on Strong H1 2026 Results and Sustained Space-Segment Momentum, Backing €56.8 Price Target
8d ago
ITOS
Vor Bio appoints Osovsky as General Counsel
PremiumThe Fly
Vor Bio appoints Osovsky as General Counsel
1y ago
VOR
ITOS
iTeos Therapeutics Completes Merger with Concentra Biosciences
PremiumCompany Announcements
iTeos Therapeutics Completes Merger with Concentra Biosciences
1y ago
8K
ITOS
GSK and iTeos Advance Immunotherapy Study for Lung Cancer
PremiumCompany Announcements
GSK and iTeos Advance Immunotherapy Study for Lung Cancer
1y ago
GSK
ITOS
GSK and iTeos Therapeutics’ Promising Phase 3 Lung Cancer Study: Market Implications
PremiumCompany Announcements
GSK and iTeos Therapeutics’ Promising Phase 3 Lung Cancer Study: Market Implications
1y ago
GSK
ITOS
iTeos Therapeutics Faces Challenges Amid Collaboration Termination
PremiumCompany AnnouncementsiTeos Therapeutics Faces Challenges Amid Collaboration Termination
1y ago
ITOS
iTeos Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Premium
The Fly
iTeos Therapeutics downgraded to Neutral from Overweight at Piper Sandler
1y ago
ITOS
Vor Bio appoints Cumbo, Detheux to board of directors
Premium
The Fly
Vor Bio appoints Cumbo, Detheux to board of directors
1y ago
VOR
ITOS
iTeos Therapeutics Announces Merger with Concentra Biosciences
PremiumCompany Announcements
iTeos Therapeutics Announces Merger with Concentra Biosciences
1y ago
8K
ITOS
iTeos to be acquired by Concentra for $10.047 per share in cash plus CVR
PremiumThe Fly
iTeos to be acquired by Concentra for $10.047 per share in cash plus CVR
1y ago
ITOS
GSK and Iteos Therapeutics’ Promising Phase 3 Study on NSCLC Treatment
PremiumCompany Announcements
GSK and Iteos Therapeutics’ Promising Phase 3 Study on NSCLC Treatment
1y ago
GSK
ITOS
GSK and iTeos Therapeutics Advance Phase 3 NSCLC Study with Belrestotug and Dostarlimab
PremiumCompany Announcements
GSK and iTeos Therapeutics Advance Phase 3 NSCLC Study with Belrestotug and Dostarlimab
1y ago
GSK
ITOS
iTeos Therapeutics Holds Annual Stockholders Meeting
PremiumCompany AnnouncementsiTeos Therapeutics Holds Annual Stockholders Meeting
1y ago
8K
ITOS
Tim Van Hauwermeiren Resigns from iTeos Board
Premium
Company Announcements
Tim Van Hauwermeiren Resigns from iTeos Board
1y ago
8K
ITOS
iTeos Therapeutics: Strategic Wind Down to Maximize Shareholder Value Amid Limited Pipeline Prospects
Premium
Ratings
iTeos Therapeutics: Strategic Wind Down to Maximize Shareholder Value Amid Limited Pipeline Prospects
1y ago
ITOS
iTeos Therapeutics downgraded to Equal Weight at Wells Fargo on wind down
PremiumThe Fly
iTeos Therapeutics downgraded to Equal Weight at Wells Fargo on wind down
1y ago
ITOS
iTeos Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
PremiumThe Fly
iTeos Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
1y ago
ITOS
iTeos Therapeutics Stock (ITOS) Booms 24% as it Winds Down and Sells Cancer Treatments
PremiumMarket News
iTeos Therapeutics Stock (ITOS) Booms 24% as it Winds Down and Sells Cancer Treatments
1y ago
ITOS
iTeos Therapeutics downgraded to Neutral at Wedbush after wind down decision
PremiumThe Fly
iTeos Therapeutics downgraded to Neutral at Wedbush after wind down decision
1y ago
ITOS
iTeos Therapeutics downgraded to Neutral from Outperform at Wedbush
PremiumThe FlyiTeos Therapeutics downgraded to Neutral from Outperform at Wedbush
1y ago
ITOS
iTeos Therapeutics Announces Strategic Wind Down Plan
Premium
Company Announcements
iTeos Therapeutics Announces Strategic Wind Down Plan
1y ago
8K
ITOS
iTeos Therapeutics announces intention to wind down operations
Premium
The Fly
iTeos Therapeutics announces intention to wind down operations
1y ago
ITOS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >